<p>尽管投资者经常忽视 <strong>道琼斯工业平均指数</strong>，更青睐 <strong>标普 500 指数</strong> 和 <strong>纳斯达克 100 指数</strong>，但道琼斯包含了一些世界上质量最高的企业。要购买的顶级道琼斯股票代表了广泛的行业范围，以其稳定性、韧性和潜力稳定增长而闻名。</p>
<p>与更具波动性的科技重点指数不同，道琼斯的成分往往是具有良好业绩记录的老牌公司。这使得道琼斯股票成为投资者生成股票投资理念的绝佳起点，尤其是那些新手投资者，希望将他们的前几千美元投入运作。</p>
<p>鉴于我已将大多数道琼斯成分视为高质量企业，我选择购买道琼斯股票的标准是专注于识别相对于增长前景而言定价最具吸引力的道琼斯股票。鉴于包括道琼斯在内的广泛指数最近已经录得实质性收益，寻找价格合理的股票以确保合理的安全边际至关重要。以下三个股票提供了出色的价值、质量和增长潜力。</p>
<h2>麦当劳（MCD）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Tama2u / Shutterstock</p>
<p>在我看来，如今道琼斯成分中最具吸引力的投资机会是 <strong>麦当劳</strong>（纽约证券交易所：<strong>MCD</strong>）。作为快餐服务领域中最重要的参与者，在全球拥有超过 41,000 家门店，其股价在 2024 年下跌约 12.5%，表现不及道琼斯和整体市场。股价下跌可以归因于市场对支付能力危机的定价，因为即使快餐似乎也变得相当昂贵，食品成本和劳动力成本最近大幅上涨。</p>
<p>尽管这些担忧是合理的，麦当劳的运营结果仍然相当稳健。尽管在公司最近的第一季度报告中，同店销售仅增长了 1.9%，这一时期标志着连续第 13 个季度实现同店销售增长。麦当劳寻常中等单数字增长率的短期停滞是可以理解的。事实上，同店销售没有下滑，并且继续从已经较高水平增长是令人印象深刻的。</p>
<p>与此同时，麦当劳股票目前仅以今年预期每股收益的 21 倍交易，低于其历史平均水平。我认为这一倍数提供了显著的安全边际和有意义的上行潜力，特别是考虑到华尔街预计麦当劳的每股收益增长将在中期加速至高个位数到低两位数。</p>
<h2>强生（JNJ）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Alexander Tolstykh / Shutterstock.com</p>
<p>道琼斯中另一个值得考虑购买的引人注目投资机会是 <strong>强生</strong>（纽约证券交易所：<strong>JNJ</strong>）。作为全球最大和最多元化的医疗保健巨头之一，强生股票很少以折扣价交易。投资者历来愿意为公司股份支付溢价，因为公司拥有众多优点，包括其长达 49 年的股息增长记录。</p>
<p>鉴于强生在投资者中赢得的传奇声誉，无论您是首次投资 1000 美元还是向投资组合再增加 1000 美元，它都是一个出色选择。这支股票几十年来一直表现良好，我认为这一趋势不会很快改变。</p>
<p>每当您可以以折扣价购买股票时，就像目前公司以仅 14 倍的前瞻市盈率交易一样，明显低于其约 17 倍至 18 倍的历史平均水平，利用折扣是明智的。</p>
<p>与此同时，强生的整体增长仍然相当强劲。公司在第一季度将其调整后的每股收益提高了 12.4%，而共识预测看到中期持续的每股收益增长率在中等单数字水平。鉴于公司倾向于超越分析师预期，这些数字进一步说明了为什么股票当前的估值相当有吸引力。</p>
<h2>美国联合健康集团（UNH）</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源：Ken Wolter / Shutterstock.com</p>
<p>我将这份清单以 <strong>美国联合健康集团</strong>（纽约证券交易所：<strong>UNH</strong>）结束，这是道琼斯中另一个值得考虑购买的落后者。2024 年 UNH 股价下跌约 11%，UNH 股票落后于其指数同行。尽管如此，UNH 股票也是一家很少以折价估值交易的公司，因此任何这样的股价滞后都是值得研究的潜在机会。</p>
<p>这似乎是情况，UNH 股票现在以非常有吸引力的估值交易，尽管其强劲的增长前景。在其第一季度业绩中，UNH 的营收增长了近 9%，达到 998 亿美元。其调整后的每股收益也增长了 10.4%，达到 6.91 美元，公司录得调整后的营运利润率扩张和股份回购，进一步促进了这一数字的增长。这一上下线增长与 UNH 的历史趋势相匹配，表明持续增长且没有放缓的迹象。</p>
<p>随着 UNH 的增长保持强劲，股价滞后，股票的估值已经压缩至相当有吸引力的水平。以今年预期调整后每股收益的 17.4 倍交易，我相信 UNH 股票提供了安全性和上行潜力的强大组合，特别是随着双位数盈利增长的持续。随着 P/E 扩张可能增加未来回报前景，UNH 股票绝对是值得您下一个 1000 美元投资的股票。</p>
<p><em>在发布日期，Nikolaos Sismanis 没有持有（直接或间接）本文提到的证券中的任何头寸。本文中表达的观点属于作者，遵守 InvestorPlace.com 的发布准则。</em></p>
<p>Nikolaos Sismanis 是一位专业的研究分析师，在股票研究和财务建模领域拥有五年的经验。Nikolaos 撰写了超过 1,000 篇与股票相关的文章，专注于发掘深度价值机会，识别合理估值的成长股，并关注被忽视的国际股票。</p>

麦当劳

联合健康

外服控股

强生

<p>道琼斯工业平均指数包括具有稳定性、韧性和增长潜力的高质量企业。麦当劳、强生和联合健康集团是三只值得考虑投资的道琼斯股票。麦当劳具有显著的安全边际和上行潜力，而强生正在以折扣价交易，并具有强劲的整体增长。联合健康集团在道琼斯指数中表现较差，但也呈现投资机会</p>

<p>While investors often overlook the <strong>Dow Jones Industrial Average</strong> in favor of the <strong>S&amp;P 500</strong> and the <strong>Nasdaq 100</strong>, the Dow comprises some of the highest-quality businesses in the world. The top Dow stocks to buy represent a broad spectrum of industries and are known for their stability, resilience, and potential for steady growth.</p>
<div class="lb-trans"><p>尽管投资者经常忽视 <strong>道琼斯工业平均指数</strong>，更青睐 <strong>标普 500 指数</strong> 和 <strong>纳斯达克 100 指数</strong>，但道琼斯包含了一些世界上质量最高的企业。要购买的顶级道琼斯股票代表了广泛的行业范围，以其稳定性、韧性和潜力稳定增长而闻名。</p>
</div><p>Unlike the more volatile tech-heavy indices, the Dow’s components tend to be established firms with strong track records. This makes Dow stocks to buy as an excellent starting point for investors to generate stock ideas, especially those new to the market and looking to put their first few thousand dollars to work.</p>
<div class="lb-trans"><p>与更具波动性的科技重点指数不同，道琼斯的成分往往是具有良好业绩记录的老牌公司。这使得道琼斯股票成为投资者生成股票投资理念的绝佳起点，尤其是那些新手投资者，希望将他们的前几千美元投入运作。</p>
</div><p>Given that I already regard most Dow components as high-quality businesses, my criteria for selecting Dow stocks to buy focused on identifying the most attractively priced Dow stocks relative to their growth prospects. With broad indices, including the Dow, having already recorded substantial gains lately, it’s essential to seek out reasonably priced stocks to ensure a decent margin of safety. The following three names offer an excellent blend of value, quality, and growth potential.</p>
<div class="lb-trans"><p>鉴于我已将大多数道琼斯成分视为高质量企业，我选择购买道琼斯股票的标准是专注于识别相对于增长前景而言定价最具吸引力的道琼斯股票。鉴于包括道琼斯在内的广泛指数最近已经录得实质性收益，寻找价格合理的股票以确保合理的安全边际至关重要。以下三个股票提供了出色的价值、质量和增长潜力。</p>
</div><h2>McDonald’s (MCD)</h2>
<div class="lb-trans"><h2>麦当劳（MCD）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Tama2u / Shutterstock</p>
<div class="lb-trans"><p>来源：Tama2u / Shutterstock</p>
</div><p>In my view, the most compelling investment opportunity amongst the Dow Jones components today is <strong>McDonald’s</strong> (NYSE:<strong>MCD</strong>). The most prominent player in the quick-service restaurant space, boasting over 41,000 locations worldwide, has seen its shares decline by about 12.5% in 2024, underperforming the Dow Jones and the overall market. The stock’s decline can be attributed to the market pricing in an affordability crisis, as even fast food seems rather expensive these days, with the cost of food ingredients and labor having surged lately.</p>
<div class="lb-trans"><p>在我看来，如今道琼斯成分中最具吸引力的投资机会是 <strong>麦当劳</strong>（纽约证券交易所：<strong>MCD</strong>）。作为快餐服务领域中最重要的参与者，在全球拥有超过 41,000 家门店，其股价在 2024 年下跌约 12.5%，表现不及道琼斯和整体市场。股价下跌可以归因于市场对支付能力危机的定价，因为即使快餐似乎也变得相当昂贵，食品成本和劳动力成本最近大幅上涨。</p>
</div><p>While these concerns are valid, McDonald’s operating results remain largely resilient. Despite a modest slowdown, with same-store sales rising by just 1.9% in the company’s most recent Q1 report, this period marked the 13th consecutive quarter of positive same-store sales growth. A short-term halt from McDonald’s usual mid-single-digit growth rates is understandable. If anything, the fact that same-store sales haven’t dipped and continue to grow from already high levels is impressive.</p>
<div class="lb-trans"><p>尽管这些担忧是合理的，麦当劳的运营结果仍然相当稳健。尽管在公司最近的第一季度报告中，同店销售仅增长了 1.9%，这一时期标志着连续第 13 个季度实现同店销售增长。麦当劳寻常中等单数字增长率的短期停滞是可以理解的。事实上，同店销售没有下滑，并且继续从已经较高水平增长是令人印象深刻的。</p>
</div><p>In the meantime, following its recent dip, McDonald’s stock trades at just 21x this year’s expected earnings per share, below its historical average. I think this multiple presents a notable margin of safety and potential for meaningful upside, especially considering Wall Street expects McDonald’s EPS growth to accelerate in the high single digits to low double digits over the medium term.</p>
<div class="lb-trans"><p>与此同时，麦当劳股票目前仅以今年预期每股收益的 21 倍交易，低于其历史平均水平。我认为这一倍数提供了显著的安全边际和有意义的上行潜力，特别是考虑到华尔街预计麦当劳的每股收益增长将在中期加速至高个位数到低两位数。</p>
</div><h2>Johnson &amp; Johnson (JNJ)</h2>
<div class="lb-trans"><h2>强生（JNJ）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Alexander Tolstykh / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Alexander Tolstykh / Shutterstock.com</p>
</div><p>Another compelling investment opportunity within the Dow to consider buying following its drop in the past year is <strong>Johnson &amp; Johnson</strong> (NYSE: <strong>JNJ</strong>). As one of the largest and most diversified healthcare giants globally, Johnson &amp; Johnson stock rarely trades at a discount. Investors have historically been willing to pay a premium for a stake in the company due to its numerous qualities, including its 49-year dividend growth track record.</p>
<div class="lb-trans"><p>道琼斯中另一个值得考虑购买的引人注目投资机会是 <strong>强生</strong>（纽约证券交易所：<strong>JNJ</strong>）。作为全球最大和最多元化的医疗保健巨头之一，强生股票很少以折扣价交易。投资者历来愿意为公司股份支付溢价，因为公司拥有众多优点，包括其长达 49 年的股息增长记录。</p>
</div><p>Given the legendary reputation Johnson &amp; Johnson has earned among investors, it stands out as an excellent choice, whether you are making your first $1,000 investment or adding another $1,000 to your portfolio. The stock has consistently performed well for decades, and I don’t see this trend changing anytime soon.</p>
<div class="lb-trans"><p>鉴于强生在投资者中赢得的传奇声誉，无论您是首次投资 1000 美元还是向投资组合再增加 1000 美元，它都是一个出色选择。这支股票几十年来一直表现良好，我认为这一趋势不会很快改变。</p>
</div><p>Whenever you can buy shares at a discount, as is currently the case with the company trading at a forward price to earnings (P/E) ratio of just 14x, notably below its historical average of around 17x to 18x, it is wise to take advantage of the discount.</p>
<div class="lb-trans"><p>每当您可以以折扣价购买股票时，就像目前公司以仅 14 倍的前瞻市盈率交易一样，明显低于其约 17 倍至 18 倍的历史平均水平，利用折扣是明智的。</p>
</div><p>In the meantime, Johnson &amp; Johnson’s overall growth remains quite strong. The company increased its adjusted EPS by 12.4% in Q1, while consensus estimates see sustained EPS growth in the mid-single digits over the medium term. Given the company’s tendency to beat analyst estimates, these numbers further expose why the stock’s current valuation is rather attractive.</p>
<div class="lb-trans"><p>与此同时，强生的整体增长仍然相当强劲。公司在第一季度将其调整后的每股收益提高了 12.4%，而共识预测看到中期持续的每股收益增长率在中等单数字水平。鉴于公司倾向于超越分析师预期，这些数字进一步说明了为什么股票当前的估值相当有吸引力。</p>
</div><h2>UnitedHealth Group (UNH)</h2>
<div class="lb-trans"><h2>美国联合健康集团（UNH）</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Ken Wolter / Shutterstock.com</p>
<div class="lb-trans"><p>来源：Ken Wolter / Shutterstock.com</p>
</div><p>I will wrap this list with <strong>UnitedHealth Group</strong>(NYSE:<strong>UNH</strong>), another laggard within the Dow worth considering. Shares are down roughly 11% in 2024, with UNH stock falling considerably behind its index peers. Still, UNH stock is also a name that rarely trades at a discounted valuation, so any such share price lags are potential opportunities worth examining.</p>
<div class="lb-trans"><p>我将这份清单以 <strong>美国联合健康集团</strong>（纽约证券交易所：<strong>UNH</strong>）结束，这是道琼斯中另一个值得考虑购买的落后者。2024 年 UNH 股价下跌约 11%，UNH 股票落后于其指数同行。尽管如此，UNH 股票也是一家很少以折价估值交易的公司，因此任何这样的股价滞后都是值得研究的潜在机会。</p>
</div><p>This seems to be the case, with UNH stock now trading at a highly compelling valuation despite its robust growth prospects. In its Q1 results, UNH grew revenues by nearly 9% to $99.8 billion. Its adjusted EPS also grew by a notable 10.4% to $6.91, with the company recording an adjusted operating margin expansion and share repurchases, further aiding the growth of this figure. This top and bottom line growth matches UNH’s historical trends, suggesting sustained growth with no signs of a slowdown.</p>
<div class="lb-trans"><p>这似乎是情况，UNH 股票现在以非常有吸引力的估值交易，尽管其强劲的增长前景。在其第一季度业绩中，UNH 的营收增长了近 9%，达到 998 亿美元。其调整后的每股收益也增长了 10.4%，达到 6.91 美元，公司录得调整后的营运利润率扩张和股份回购，进一步促进了这一数字的增长。这一上下线增长与 UNH 的历史趋势相匹配，表明持续增长且没有放缓的迹象。</p>
</div><p>With UNH’s growth remaining robust against a lagging share price, the stock has compressed its valuation to rather attractive levels. At 17.4x this year’s expected adjusted EPS, I believe that UNH stock provides a potent mix of safety and upside, particularly with double-digit earnings growth persisting. With the possibility of a P/E expansion adding to future return prospects, UNH is certainly a stock worth your next $1000.</p>
<div class="lb-trans"><p>随着 UNH 的增长保持强劲，股价滞后，股票的估值已经压缩至相当有吸引力的水平。以今年预期调整后每股收益的 17.4 倍交易，我相信 UNH 股票提供了安全性和上行潜力的强大组合，特别是随着双位数盈利增长的持续。随着 P/E 扩张可能增加未来回报前景，UNH 股票绝对是值得您下一个 1000 美元投资的股票。</p>
</div><p><em>On the date of publication, Nikolaos Sismanis did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.</em></p>
<div class="lb-trans"><p><em>在发布日期，Nikolaos Sismanis 没有持有（直接或间接）本文提到的证券中的任何头寸。本文中表达的观点属于作者，遵守 InvestorPlace.com 的发布准则。</em></p>
</div><p>Nikolaos Sismanis is a professional research analyst with five years of experience in the field of equity research and financial modeling. Nikolaos has authored over 1,000 stock-related articles that focus on uncovering deep value opportunities, identifying growth stocks at reasonable valuations, and shining a spotlight on overlooked international equities.</p>
<div class="lb-trans"><p>Nikolaos Sismanis 是一位专业的研究分析师，在股票研究和财务建模领域拥有五年的经验。Nikolaos 撰写了超过 1,000 篇与股票相关的文章，专注于发掘深度价值机会，识别合理估值的成长股，并关注被忽视的国际股票。</p>
</div>

现在用 1000 美元购买的三只最明智的道琼斯股票